Form 4: Mirum Pharmaceuticals Director Acquires Stock Options and Deferred Stock Units

A Form 4 filing reveals that Michael G. Grey, a director at Mirum Pharmaceuticals, acquired stock options and deferred stock units on June 5, 2024.

Summary

• Michael G. Grey, a director at Mirum Pharmaceuticals, filed a Form 4 with the SEC.
• The filing reports transactions that occurred on June 5, 2024.
• Grey acquired 8,779 stock options with an exercise price of $26.30.
• These options vest on the first anniversary of the grant date or fully vest by the date of the Issuer's 2025 annual stockholder meeting.
• Grey also acquired 5,703 deferred stock units, each representing a contingent right to receive one share of Mirum's common stock.
• These deferred stock units vest on the first anniversary of the grant date or fully vest by the date of the Issuer's 2025 annual stockholder meeting.
• Vested deferred stock units will be paid out in common stock upon a change in control of the Issuer or within 60 days following separation from service.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options and deferred stock units by a director suggests confidence in the company's future, but it's a routine transaction.

Positives

• The acquisition of stock options and deferred stock units by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the director's increased stake in the company.

Stakeholder Impact

• The acquisition of stock options and deferred stock units by a director could have a slightly positive impact on shareholders, as it signals confidence in the company's future performance.

Key Dates